OSI Systems, Inc. — Form 10-Q Summary
Business Context and Reporting Period
OSI Systems designs and manufactures specialized electronic systems and components for security, healthcare, defense, aerospace and related applications. Its three operating divisions are Security, Optoelectronics and Manufacturing, and Healthcare.
This unaudited Form 10-Q covers the three months ended September 30, 2023, the first quarter of fiscal 2024, compared with the three months ended September 30, 2022. The company operates globally and reported approximately 91% of its $82.6 million of cash at foreign subsidiaries.
Financial Performance and Position
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Net revenues | $279.2 million | $268.1 million | Up 4.1% |
| Gross profit | $98.7 million | $87.5 million | Up 12.9% |
| Gross margin | 35.4% | 32.6% | Up 280 basis points |
| Income from operations | $22.6 million | $18.3 million | Up 23.3% |
| Operating margin | 8.1% | 6.8% | Improved |
| Net income | $12.9 million | $11.2 million | Up 14.6% |
| Diluted EPS | $0.75 | $0.65 | Up $0.10 |
| Cash flow from operations | $17.1 million | $17.2 million | Approximately flat |
Security revenue increased 14% to $164.6 million, driven primarily by product deliveries under new Mexico contracts and higher service revenue from the installed base. Optoelectronics and Manufacturing revenue declined 3% to $76.8 million, while Healthcare revenue declined 13% to $37.8 million.
Cash and cash equivalents were $82.6 million at September 30, 2023, compared with $76.8 million at June 30, 2023. Accounts receivable declined to $323.8 million from $380.8 million, while inventories increased materially to $418.8 million from $338.0 million.
Net cash used in investing activities was $9.6 million, including $5.2 million of capital expenditures and $4.2 million for intangible and other assets. Net cash used in financing activities was $1.9 million. The company did not repurchase shares during the quarter.
At September 30, 2023, debt included $235.0 million outstanding under the revolving credit facility, $141.3 million under the term loan, and $56.8 million under foreign bank lines primarily supporting letters of credit. The company had $327.3 million available under the revolving facility, subject to facility conditions, and $37.7 million of outstanding letters of credit. Total reported debt, including current and long-term portions, was approximately $378.0 million. The company was in compliance with its financial covenants.
Material Changes Versus the Prior Comparable Period
- Revenue increased $11.1 million, led by a $19.6 million increase in Security revenue, partially offset by declines in Optoelectronics and Manufacturing and Healthcare.
- Gross margin expanded to 35.4%, primarily because of a more favorable Security sales mix. The benefit was partly offset by lower Healthcare sales, which generally carry the highest margin.
- SG&A increased $6.4 million, primarily reflecting a prior-year foreign exchange benefit and lower recovery of accounts receivable losses in the current quarter.
- Research and development expense increased $1.4 million as the company invested in new product initiatives, primarily in Security and Healthcare.
- Interest and other expense increased to $5.7 million from $3.4 million because of higher interest rates and higher average borrowings. The prior-year period included the 1.25% convertible notes before their September 1, 2022 retirement.
- Impairment, restructuring and other charges declined to $0.5 million from $1.2 million.
- Cash from operations was essentially unchanged despite higher net income, as working-capital movements offset the earnings increase. Inventory growth was a significant use of cash.
- The company reported approximately $906.2 million of remaining performance obligations at September 30, 2023, with approximately 67% expected to be recognized over the next 12 months.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide specific quantitative revenue or earnings guidance. Management stated that available funds, credit facilities and operating cash flow are expected to satisfy operational needs for the next 12 months and the foreseeable future.
Management highlighted two significant international Security contracts awarded in fiscal 2023 with an aggregate value greater than $700 million and expected revenue recognition over multiple years. The filing also notes continuing uncertainty from inflation, higher interest rates, labor shortages, supply-chain constraints, component and freight availability, foreign exchange movements, government procurement and budget conditions, and geopolitical conflicts including Russia-Ukraine and Israel-Hamas developments.
The company identified potential effects from U.S. government continuing resolutions or shutdowns, changing trade policies and tariffs, cybersecurity or information-security incidents, contract and regulatory compliance matters, customer acceptance delays, order cancellations and weaker hospital capital spending.
In February 2023, a subsidiary received a U.S. Department of Justice subpoena concerning a former employee and business dealings in Mexico and stated that it is cooperating. In September 2023, an employee demanded $4.0 million alleging retaliation related to an alleged solicitation of a payment by a Mexican government official. The company denied the claim and stated that no payment was made and the related $35 million opportunity was not awarded. No loss contingency was accrued for these matters because management does not consider an adverse outcome probable and reasonably estimable.
Other notable obligations include up to $45.0 million of potential future capped acquisition-related contingent consideration payments and a $13.5 million bonus payable to the Chief Executive Officer, contingent primarily on continued employment through January 1, 2024. The company has not paid dividends since its 1997 initial public offering and does not currently intend to pay dividends.
Important Facts for Investors to Verify
- Whether Security contract deliveries, particularly in Mexico and under the fiscal 2023 international awards, continue on schedule and convert remaining performance obligations into revenue and cash.
- Whether the substantial increase in inventory is converted into sales without excess or obsolete inventory charges.
- The effect of higher interest rates and borrowing levels on future interest expense, leverage and covenant headroom.
- The concentration of cash at foreign subsidiaries and any tax, repatriation or liquidity constraints affecting U.S. funding.
- Developments in the Department of Justice inquiry, the employee retaliation claim and any related compliance, regulatory or contract consequences.
- Whether supply-chain, freight, labor, inflation and foreign-exchange pressures affect margins or delivery schedules.
- Healthcare demand trends, including hospital budget pressure and reduced patient-monitoring sales.
- The company’s ability to maintain operating cash flow while funding capital expenditures, intangible investments and contingent acquisition payments.